7:30 am Networking Breakfast
8:50 am Chair’s Opening Remarks
Executing Clinical Trials to Effectively Prove the Clinical Utility of Liquid Biopsy & Inform Patient Treatment Decisions
9:00 am Demonstrating Clinical Utility of Blood Testing
Synopsis
• Genentech’s innovative BFAST trial: Goals, design, and future directions of a blood-only 1L NSCLC trial
• Clinical results from BFAST Cohort A: Blood-identified ALK+ patients treated with alectinib
9:30 am Early Monitoring of cfDNA in Lung Cancer: What Can We Learn from the ALK+ NSCLC case?
Synopsis
• Decreased cfDNA dVAF at 6 weeks was associated with response
• Deeper decreases in cfDNA dVAF at 6 weeks were associated with more prolonged PFS and OS
• Early cfDNA dynamics may predict lorlatinib efficacy in ALK-positive metastatic NSCLC
10:00 am Morning Refreshments
10:30 am Liquid Biopsy in the Clinic: Lessons from Use in Clinical Care & Clinical Trials
Synopsis
• Become familiar with the ‘compartment of origin’ challenge for liquid biopsy interpretation
• Compare sensitivity and positive predictive value considerations for liquid biopsy
• Review established and emerging genomic mechanisms of resistance for targeted therapy for solid tumors and the ability of liquid biopsy to detect them
11:00 am Session Q+A
Synopsis
Bringing together the perspectives of the session’s expert speakers, this is your chance to challenge viewpoints, ask any pending questions or bring new discussion points key to advancing clinical trial design, execution and clinical utility demonstration.
• How can we maximize patient enrolment in large clinical trials?
• Exploring strategies to navigate the analysis of large datasets to analyse relevant, applicable data and draw actionable conclusions to prove utility
• What lessons have been learned from published or unpublished comparative trials to inform end-end drug development?
• Establishing a set of minimal reporting and analysis criteria to be introduced to better understand your study’s quality
12:00 pm Networking Lunch
Improving Patient-Centricity & Standard of Care
1:00 pm How “Liquid Biopsies” – Circulating Tumor DNA (ctDNA) Testing Are Allowing Precision Medicine in Clinic & Trials For Our Gastrointestinal Cancer Patients
Synopsis
• Feasibility and value of integrating “liquid biopsies” – circulating tumor DNA (ctDNA) testing in patients with gastrointestinal cancers
• Patient- and tumor-related factors pertaining to utility of ctDNA testing
• Clinical trials incorporating the use of liquid biopsies for patients with gastrointestinal cancers
• How liquid biopsies are allowing the promise of precision medicine to be delivered in clinic for our cancer patients
1:30 pm Reducing Liquid Biopsy Results to (Routine) Clinical Practice
Synopsis
• Liquid Biopsies have become the preferred sample type in treatment decisions formany cancer patients
• Interpretation of Liquid Biopsy results remain problematic for many technical and administrative reasons, delaying a more rapid uptake for clinical decision-making
• The early results reported here are from an FNIH Consortium to validate commercial ctDNA control material to FDA-requirement levels, enhancing confidence in ctDNA results
2:00 pm Roundtable Discussion: Liquid Biopsies In the Clinic
Synopsis
• How are perceptions on liquid biopsy beginning to shift in healthcare? Where does future opportunity lie?
• Is liquid biopsy becoming more widely accepted in pathology?
• How do we combat the cost challenges associated with large randomized clinical trials?
• How can effective partnerships and wider industry advancements help drive patient-centricity in personalized therapeutics?